This Article Abstract Full Text Full Text (PDF) Get for this article Online Appendix View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Tikkanen, M. J. Search for Related Content PubMed PubMed Citation Articles by Tikkanen, M. J. Related Collections Related Articles

Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy

Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial

Matti J. Tikkanen, MD, PhD^_*,_*, Michael Szarek, PhD, Rana Fayyad, PhD, Ingar Holme, PhD, Nilo B. Cater, MD, Ole Faergeman, MD, DMSc, John J.P. Kastelein, MD, PhD^||, Anders G. Olsson, MD, PhD^#, Mogens Lytken Larsen, MD, DMSc, Christina Lindahl, MD^_**, Terje R. Pedersen, MD, PhD for the IDEAL Investigators

^_* Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
Pfizer Inc., New York, New York
Centre of Preventive Medicine, Ullevål University Hospital, Oslo, Norway
Department of Medicine-Cardiology A, Århus University Hospital, Århus, Denmark
^|| Department of Vascular Medicine, Academic Hospital Amsterdam, Amsterdam, the Netherlands
^# Department of Internal Medicine, Faculty of Health Sciences, University Hospital, Linköping, Sweden
^_** Pfizer Sweden, Sollentuna, Sweden

View larger version (55K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Flow of Participants Through the IDEAL Trial

View larger version (11K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Effects of Atorvastatin 80 mg Daily Versus Simvastatin 20 to 40 mg Daily on Any Cardiovascular Event Effects are a composite of the following: fatal or nonfatal myocardial infarction, resuscitated cardiac arrest, stroke, hospitalization for unstable angina pectoris, coronary revascularization procedures, peripheral vascular disease, and hospitalization for nonfatal congestive heart failure. *Adjusted for sex and age at baseline. CI = confidence interval.